AC
XENE icon

Athanor Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Athanor Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,077
Closed -$180K – 802
2021
Q1 		$180K Sell
10,077
-16,550
-62% -$281K ﹤0.01% 750
2020
Q4 		$410K Buy
26,627
+2,060
+8% +$24.1K 0.01% 511
2020
Q3 		$272K Sell
24,567
-1,401
-5% -$16.5K 0.01% 445
2020
Q2 		$326K Buy
+25,968
New +$330K 0.02% 389
2019
Q3 		– Sell
-10,100
Closed -$100K – 235
2019
Q2 		$100K Buy
+10,100
New +$96.6K 0.01% 141

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Athanor Capital's XENE Position: Q2 2021 in Review

Athanor Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2021, closing a stake of 10,077 shares — an estimated $180K sold.

Athanor Capital first reported a position in XENE in Q2 2019 and held it in 5 quarters. The position peaked at $410K in Q4 2020. 103 funds tracked by Wall St. Rank hold XENE as of Q2 2021.

  • Athanor Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 10,077 Xenon Pharmaceuticals shares in Q2 2021, an estimated $180K.
  • Athanor Capital first reported a position in Xenon Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Athanor Capital's Xenon Pharmaceuticals position peaked at $410K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.